acetoacetic acid has been researched along with Diabetes Mellitus, Adult-Onset in 21 studies
acetoacetic acid : A 3-oxo monocarboxylic acid that is butyric acid bearing a 3-oxo substituent.
Excerpt | Relevance | Reference |
---|---|---|
" In order to study the effect of HMG-CoA reductase inhibitor (pravastatin) on ketone formation, changes in the plasma levels of ketone bodies by treatment with pravastatin were studied in 18 non-insulin dependent diabetics with hypercholesterolemia." | 7.70 | Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia. ( Chiba, T; Fukuda, M; Nagakubo, H; Ogawa, S; Oouchi, M; Sato, C; Sato, T; Sugimura, K, 1998) |
"Three clinical studies were conducted: a bariatric surgery cohort study of participants with morbid obesity who underwent either Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) studied over four and twelve weeks, and two randomized placebo-controlled, crossover double blind studies of liraglutide vs." | 5.69 | Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity. ( Alexandrou, A; Angelidi, AM; Connelly, MA; Kokkinos, A; Mantzoros, CS; Mingrone, G; Sanoudou, D, 2023) |
"Euglycaemic ketoacidosis has been reported after sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment." | 5.48 | Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes. ( Baek, SI; Choi, SH; Jang, HC; Kim, KM; Lee, DH; Lim, S; Min, SH; Moon, JH; Oh, TJ; Park, KS, 2018) |
" As alterations in hepatic gluconeogenesis and glycogen metabolism are hallmarks that characterize insulin resistance and type 2 diabetes, we tested whether imposed changes in the extracellular redox state could modulate these processes." | 3.81 | The extracellular redox state modulates mitochondrial function, gluconeogenesis, and glycogen synthesis in murine hepatocytes. ( Corkey, BE; Jones Iv, AR; Kleckner, AS; Liesa, M; Nocito, L; Yoo, EJ, 2015) |
" In order to study the effect of HMG-CoA reductase inhibitor (pravastatin) on ketone formation, changes in the plasma levels of ketone bodies by treatment with pravastatin were studied in 18 non-insulin dependent diabetics with hypercholesterolemia." | 3.70 | Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia. ( Chiba, T; Fukuda, M; Nagakubo, H; Ogawa, S; Oouchi, M; Sato, C; Sato, T; Sugimura, K, 1998) |
"A complication of diabetes is diabetic ketoacidosis (DKA), which if left untreated is a life threatening condition." | 2.53 | Evaluation of the Accuracy of Capillary Hydroxybutyrate Measurement Compared with Other Measurements in the Diagnosis of Diabetic Ketoacidosis: A Systematic Review. ( Brooke, J; Ojo, O; Stiell, M, 2016) |
"Severe hypertriglyceridemia was considered to have been a consequence of impaired insulin action and his apolipoprotein E4/2 phenotype." | 1.51 | Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2. ( Aiba, S; Imai, J; Katagiri, H; Kikuchi, K; Kohata, M; Kurosawa, S; Nakajima, T; Satake, C; Sawada, S; Takahashi, K; Takeda, K; Tsuchiya, S, 2019) |
"Soft-drink diabetic ketosis, characterized by acute onset ketosis induced by excessive ingestion of sugar-containing drinks, is often seen in obese, young patients, even with undiagnosed type 2 diabetes." | 1.51 | Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2. ( Aiba, S; Imai, J; Katagiri, H; Kikuchi, K; Kohata, M; Kurosawa, S; Nakajima, T; Satake, C; Sawada, S; Takahashi, K; Takeda, K; Tsuchiya, S, 2019) |
"The eruptive xanthoma lesions gradually diminished in size and number and eventually disappeared by 12 months." | 1.51 | Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2. ( Aiba, S; Imai, J; Katagiri, H; Kikuchi, K; Kohata, M; Kurosawa, S; Nakajima, T; Satake, C; Sawada, S; Takahashi, K; Takeda, K; Tsuchiya, S, 2019) |
"Euglycaemic ketoacidosis has been reported after sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment." | 1.48 | Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes. ( Baek, SI; Choi, SH; Jang, HC; Kim, KM; Lee, DH; Lim, S; Min, SH; Moon, JH; Oh, TJ; Park, KS, 2018) |
"Breath acetone of the type 2 diabetes mellitus patients showed positive correlations with plasma glucose when the level of plasma glucose tended to decrease during hospitalization." | 1.40 | Analysis of ketone bodies in exhaled breath and blood of ten healthy Japanese at OGTT using a portable gas chromatograph. ( Hinokio, Y; Koseki, T; Takahashi, N; Tanda, N; Washio, J, 2014) |
"Our results suggest that genetic susceptibility plays an important role in inducing underdevelopment and NTD in cultured CDs embryos in sub-teratogenic medium and in protecting the CDr embryos under the same conditions." | 1.32 | Reduced SOD activity and increased neural tube defects in embryos of the sensitive but not of the resistant Cohen diabetic rats cultured under diabetic conditions. ( Ornoy, A; Weksler-Zangen, S; Yaffe, P, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (9.52) | 18.7374 |
1990's | 7 (33.33) | 18.2507 |
2000's | 2 (9.52) | 29.6817 |
2010's | 9 (42.86) | 24.3611 |
2020's | 1 (4.76) | 2.80 |
Authors | Studies |
---|---|
Angelidi, AM | 1 |
Kokkinos, A | 1 |
Sanoudou, D | 1 |
Connelly, MA | 1 |
Alexandrou, A | 1 |
Mingrone, G | 1 |
Mantzoros, CS | 1 |
Min, SH | 1 |
Oh, TJ | 1 |
Baek, SI | 1 |
Lee, DH | 1 |
Kim, KM | 1 |
Moon, JH | 1 |
Choi, SH | 1 |
Park, KS | 1 |
Jang, HC | 1 |
Lim, S | 1 |
Polidori, D | 1 |
Iijima, H | 1 |
Goda, M | 1 |
Maruyama, N | 1 |
Inagaki, N | 1 |
Crawford, PA | 1 |
Tsuchiya, S | 1 |
Sawada, S | 1 |
Takeda, K | 1 |
Takahashi, K | 1 |
Nakajima, T | 1 |
Kohata, M | 1 |
Kurosawa, S | 1 |
Satake, C | 1 |
Imai, J | 1 |
Kikuchi, K | 1 |
Aiba, S | 1 |
Katagiri, H | 1 |
Mahendran, Y | 1 |
Vangipurapu, J | 1 |
Cederberg, H | 1 |
Stancáková, A | 1 |
Pihlajamäki, J | 1 |
Soininen, P | 1 |
Kangas, AJ | 1 |
Paananen, J | 1 |
Civelek, M | 1 |
Saleem, NK | 1 |
Pajukanta, P | 1 |
Lusis, AJ | 1 |
Bonnycastle, LL | 1 |
Morken, MA | 1 |
Collins, FS | 1 |
Mohlke, KL | 1 |
Boehnke, M | 1 |
Ala-Korpela, M | 1 |
Kuusisto, J | 1 |
Laakso, M | 1 |
Tanda, N | 1 |
Hinokio, Y | 1 |
Washio, J | 1 |
Takahashi, N | 1 |
Koseki, T | 1 |
Nocito, L | 1 |
Kleckner, AS | 1 |
Yoo, EJ | 1 |
Jones Iv, AR | 1 |
Liesa, M | 1 |
Corkey, BE | 1 |
Brooke, J | 1 |
Stiell, M | 1 |
Ojo, O | 1 |
Vigili de Kreutzenberg, S | 1 |
Avogaro, A | 1 |
Oh, SJ | 1 |
Choi, JM | 1 |
Yun, KU | 1 |
Oh, JM | 1 |
Kwak, HC | 1 |
Oh, JG | 1 |
Lee, KS | 1 |
Kim, BH | 1 |
Heo, TH | 1 |
Kim, SK | 1 |
Harano, Y | 2 |
Weksler-Zangen, S | 1 |
Yaffe, P | 1 |
Ornoy, A | 1 |
Kosugi, K | 1 |
Hyosu, T | 1 |
Suzuki, M | 2 |
Hidaka, H | 1 |
Kashiwagi, A | 1 |
Uno, S | 1 |
Shigeta, Y | 1 |
Nicholson, JK | 1 |
O'Flynn, MP | 1 |
Sadler, PJ | 1 |
Macleod, AF | 1 |
Juul, SM | 1 |
Sönksen, PH | 1 |
Akanji, AO | 1 |
Osifo, E | 1 |
Kirk, M | 1 |
Hockaday, TD | 1 |
Pounder, DJ | 1 |
Stevenson, RJ | 1 |
Taylor, KK | 1 |
Sato, T | 1 |
Oouchi, M | 1 |
Nagakubo, H | 1 |
Chiba, T | 1 |
Ogawa, S | 1 |
Sato, C | 1 |
Sugimura, K | 1 |
Fukuda, M | 1 |
McGarry, JD | 1 |
Watanabe, T | 1 |
Sugiyama, H | 1 |
Uchimura, I | 1 |
Maezawa, H | 1 |
Kosegawa, I | 1 |
Miura, S | 1 |
Negishi, K | 1 |
Itabashi, A | 1 |
Katayama, S | 1 |
Ishii, J | 1 |
Kamata, S | 1 |
Fujita, C | 1 |
Henry, RR | 1 |
Brechtel, G | 1 |
Lim, KH | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Comparative Study of the Effects of Roux en Y Gastric Bypass and Sleeve Gastrectomy on Postprandial Gut Hormone Responses, Glycemia and Lipid Profile, Weight Loss, and Indices of Cardiovascular Risk[NCT03851874] | 28 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI[NCT01562678] | Phase 4 | 28 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
Saxenda: Underlying Mechanisms and Clinical Outcomes[NCT02944500] | Phase 4 | 28 participants (Actual) | Interventional | 2016-11-30 | Active, not recruiting | ||
Development of Ketoacidosis During the Perioperative Period: an Observational Study 'The DKAP Study'[NCT05225467] | 58 participants (Actual) | Observational [Patient Registry] | 2022-03-15 | Completed | |||
Modulating Physiologic Effects Of Phospholipid Metabolism In Obesity And Diabetes; AIM 4: Composition and Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome[NCT02122666] | 100 participants (Anticipated) | Observational | 2014-03-31 | Active, not recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Effect size (region of interest z-scores, derived from z-maps of the brain) shown below is the difference in parietal cortex activation to highly desirable (high fat or high calorie, e.g. cakes, pies, fries) versus less desirable (low fat or low calorie, e.g. vegetables, fruits) food cues for each treatment condition (liraglutide or placebo) at the end of the treatment period. (NCT01562678)
Timeframe: 18 days of Liraglutide or placebo treatment
Intervention | z-scores of activation in cortex (Mean) |
---|---|
Liraglutide | -0.42 |
Placebo | 0.53 |
2 reviews available for acetoacetic acid and Diabetes Mellitus, Adult-Onset
Article | Year |
---|---|
Evaluation of the Accuracy of Capillary Hydroxybutyrate Measurement Compared with Other Measurements in the Diagnosis of Diabetic Ketoacidosis: A Systematic Review.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dia | 2016 |
[Blood level of ketone bodies and its clinical significance].
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Biomarkers; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type | 2002 |
3 trials available for acetoacetic acid and Diabetes Mellitus, Adult-Onset
Article | Year |
---|---|
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Biological Variation, Population; Blood Glucose; Canagliflozin | 2018 |
The effects of changes in plasma nonesterified fatty acid levels on oxidative metabolism during moderate exercise in patients with non-insulin-dependent diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Blood Glucose; Calorimetry, Indirect; Diabetes Mellitus, Type | 1993 |
16 other studies available for acetoacetic acid and Diabetes Mellitus, Adult-Onset
Article | Year |
---|---|
Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Aged; Benzhydryl Compounds; Case-Control Studies; Diabe | 2018 |
Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adolescent; Apolipoprotein E2; Apolipoprotein E4; Carbonated B | 2019 |
Association of ketone body levels with hyperglycemia and type 2 diabetes in 9,398 Finnish men.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Area Under Curve; Biomarkers; Blood Glucose; Diabetes Mellitus | 2013 |
Analysis of ketone bodies in exhaled breath and blood of ten healthy Japanese at OGTT using a portable gas chromatograph.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetone; Adult; Asian People; Blood Glucose; Breath Tests; Chr | 2014 |
The extracellular redox state modulates mitochondrial function, gluconeogenesis, and glycogen synthesis in murine hepatocytes.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Animals; Cysteine; Cystine; Diabetes Mellitus, Type 2; Glucone | 2015 |
The role of point-of-care 3-hydroxybutyrate testing in patients with type 2 diabetes undergoing coronary angiography.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Blood Glucose; Coronary Angiography; Coronary Disease; D | 2017 |
Hepatic expression of cytochrome P450 in type 2 diabetic Goto-Kakizaki rats.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Animals; Blood Glucose; Cytochrome P-450 CYP1A1; Cytochrome P- | 2012 |
Reduced SOD activity and increased neural tube defects in embryos of the sensitive but not of the resistant Cohen diabetic rats cultured under diabetic conditions.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Animals; Catalase; Diabetes Mellitus, Type 2; Disease Models, | 2003 |
Ketone bodies as markers for type 1 (insulin-dependent) diabetes and their value in the monitoring of diabetic control.
Topics: Acetoacetates; Adolescent; Adult; Aged; Blood Glucose; Child; Circadian Rhythm; Diabetes Mellitus, T | 1984 |
Proton-nuclear-magnetic-resonance studies of serum, plasma and urine from fasting normal and diabetic subjects.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetone; Adult; Amino Acids; Diabetes Mellitus, Type 1; Diabet | 1984 |
Alcoholic ketoacidosis at autopsy.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetone; Adolescent; Adult; Aged; Aged, 80 and over; Alcoholis | 1998 |
Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Aged, 80 and over; Body Mass Index; Cholesterol; Diabete | 1998 |
What if Minkowski had been ageusic? An alternative angle on diabetes.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adipose Tissue; Blood Glucose; Diabetes Mellitus, Type 1; Diab | 1992 |
Serum ketone response to glucagon as a marker of insulin dependency in diabetics.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Biomarkers; Blood Glucose; C-Peptide; Diabetes Mellitus | 1991 |
Blood ketone bodies in NIDDM: relationship with diabetic control and endogenous insulin secretion.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Die | 1991 |
Effects of ketone bodies on carbohydrate metabolism in non-insulin-dependent (type II) diabetes mellitus.
Topics: Acetoacetates; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gluc | 1990 |